VIROPTIC Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Viroptic, and what generic alternatives are available?
Viroptic is a drug marketed by Monarch Pharms and is included in one NDA.
The generic ingredient in VIROPTIC is trifluridine. There are two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the trifluridine profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Viroptic
A generic version of VIROPTIC was approved as trifluridine by SANDOZ on October 6th, 1995.
Summary for VIROPTIC
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 91 |
Clinical Trials: | 1 |
Patent Applications: | 4,211 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for VIROPTIC |
DailyMed Link: | VIROPTIC at DailyMed |
Recent Clinical Trials for VIROPTIC
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
National Eye Institute (NEI) | Phase 2 |
Anatomical Therapeutic Chemical (ATC) Classes for VIROPTIC
US Patents and Regulatory Information for VIROPTIC
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Monarch Pharms | VIROPTIC | trifluridine | SOLUTION/DROPS;OPHTHALMIC | 018299-001 | Approved Prior to Jan 1, 1982 | AT | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |